Difference between revisions of "Team:NCTU Formosa"

Line 114: Line 114:
 
font-size: 18px;
 
font-size: 18px;
 
text-decoration:none;
 
text-decoration:none;
text-align:left;
+
text-align: justify;
 
margin-left : 8%;
 
margin-left : 8%;
 
width:80%;
 
width:80%;
Line 135: Line 135:
 
font-size: 18px;
 
font-size: 18px;
 
text-decoration:none;
 
text-decoration:none;
text-align:left;
+
text-align: justify;
 
position:absolute;
 
position:absolute;
 
top:50%;
 
top:50%;
Line 158: Line 158:
 
font-size: 18px;
 
font-size: 18px;
 
text-decoration:none;
 
text-decoration:none;
text-align:left;
+
text-align: justify;
 
position:absolute;
 
position:absolute;
 
top:50%;
 
top:50%;

Revision as of 14:34, 18 September 2015

The only thing we can detect is everything.

Who are we

NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO devoted to developing detection technology by uti- lizing antibodies. In 2015, We cooperated with iGEM with Synthetic Biology to develop a brand new detection platform.

What's new

APOllO E.Cotector:
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen -antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.

What do we care

In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.